Journal of Hepato-Biliary-Pancreatic Surgery

, Volume 16, Issue 2, pp 131–136

Quality control for clinical islet transplantation: organ procurement and preservation, the islet processing facility, isolation, and potency tests

  • Toshiyuki Yamamoto
  • Akihiko Horiguchi
  • Masahiro Ito
  • Hideo Nagata
  • Hirohito Ichii
  • Camillo Ricordi
  • Shuichi Miyakawa
Topics HBP treatment using cell transplantation in the near future


Pancreatic islet transplantation has become one of the ideal treatments for patients with type 1 diabetes mellitus due to improvements in isolation techniques and immunosuppression regimens. In order to ensure the safety and rights of patients, isolated islets need to meet the criteria for regulation as both a biological product and a drug product. For the constant success of transplantation, therefore, all investigators involved in clinical islet transplantation must strive to ensure the safety, purity, and potency of islets in all the phases of clinical islet isolation and transplantation. In this review, we summarize the quality control for clinical islet isolation and transplantation, and the latest topics of pre-transplant islet assessment.


Clinical islet transplantation Quality control Islet potency test 


  1. 1.
    Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230.PubMedCrossRefGoogle Scholar
  2. 2.
    Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318.PubMedCrossRefGoogle Scholar
  3. 3.
    Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant. 2005;5:2037.PubMedCrossRefGoogle Scholar
  4. 4.
    Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37:413.PubMedCrossRefGoogle Scholar
  5. 5.
    Ichii H, Pileggi A, Molano RD, et al. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant. 2005;5:21.PubMedCrossRefGoogle Scholar
  6. 6.
    Ichii H, Wang X, Messinger S, et al. Improved human islet isolation using nicotinamide. Am J Transplant. 2006;6:2060.PubMedCrossRefGoogle Scholar
  7. 7.
    Weber DJ, McFarland RD, Irony I. Selected food and drug administration review issues for regulation of allogeneic islets of Langerhans as somatic cell therapy. Transplantation. 2002;74:1816–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Zoon KC. Dear colleague letter to transplant centers. Allogeneic pancreatic islets for transplantation. Center for Biologics Evaluation and Research (September 2000). Accessed 3 Dec 2008.
  9. 9.
    O’Gorman D, Kin T, Murdoch T, et al. The standardization of pancreatic donors for islet isolations. Transplantation. 2005;27;80(6):801–6.CrossRefGoogle Scholar
  10. 10.
    Zeng Y, Torre MA, Karrison T, Thistlethwaite JR. The correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994;57(6):954.PubMedCrossRefGoogle Scholar
  11. 11.
    Hanley SC, Paraskevas S, Rosenberg L. Donor and isolation variables predicting human islet isolation success. Transplantation. 2008;15;85(7):950–5.CrossRefGoogle Scholar
  12. 12.
    Kin T, Murdoch TB, Shapiro AM, et al. Estimation of pancreas weight from donor variables. Cell Transplant. 2006;15(2):181–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Brandhorst H, Brandhorst D, Hering BJ, et al. Body mass index of pancreatic donors: a decisive factor for human islet isolation. Exp Clin Endocrinol Diabetes. 1995;103(Suppl 2):23–6.PubMedGoogle Scholar
  14. 14.
    Lakey JR, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation. 1996;61(7):1047.PubMedCrossRefGoogle Scholar
  15. 15.
    Ponte GM, Pileggi A, Messinger S, et al. Toward maximizing the success rates of human islet isolation: influence of donor and isolation factors. Cell Transplant. 2007;16(6):595.PubMedGoogle Scholar
  16. 16.
    US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) 2007.Google Scholar
  17. 17.
    Brandhorst H, Klitscher D, Hering BJ, et al. Influence of organ procurement on human islet isolation. Horm Metab Res. 1993;25:51–2.Google Scholar
  18. 18.
    Kneteman NM, Lakey JRT, Warnock GL, et al. Pancreas procurement and preservation: impact on islet recovery and viability. Transplantation. 1994;58(10):1114–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ricordi C, editor. Pancreatic islet cell transplantation; 1892–1991. One century of transplantation for diabetes. Austin: RG Landes; 1992.Google Scholar
  20. 20.
    Kneteman NM, Lakey JR, Kizilisik TA, et al. Cadaver pancreas recovery technique. Impact on islet recovery and in vitro function. Transplantation. 1994;58:1114–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Kneteman NM, Lakey JRT, Warnock GL, et al. Human islet isolation after prolonged cold storage. Diabetes Nutr Metab. 1992;5(Suppl 1):33–7.Google Scholar
  22. 22.
    Federlin K, Bretzel RG, Hering BJ. International islet transplant registry. Newsletter no 4, 1993.Google Scholar
  23. 23.
    Straatsburg IH, Abrahamse SL, Song SW, et al. Evaluation of rat liver apoptotic and necrotic cell death after cold storage using UW, HTK, and Celsior. Transplantation. 2002;27;74(4):458–64.CrossRefGoogle Scholar
  24. 24.
    Pokorny H, Rasoul-Rockenschaub S, Langer F, et al. Histidine–tryptophan–ketoglutarate solution for organ preservation in human liver transplantation—a prospective multi-centre observation study. Transpl Int. 2005;17(5):256–60.CrossRefGoogle Scholar
  25. 25.
    Leo Roels, Willy Coosemans, Jan Donck, Bart Maes, Jacques Peeters, Johan Vanwalleghem. Inferior outcome of cadaveric kidney preserved for more than 24 hr in Histidine–Tryptophan–Ketoglutarate solution 1. Transplantation. 1998;66(12):1660–4.CrossRefGoogle Scholar
  26. 26.
    Payam Salehi, Hansen Michael A, Avila Jose G, et al. Human islet isolation outcomes from pancreata preserved with histidine–tryptophan–ketoglutarate versus University of Wisconsin Solution. Transplantation. 2006;82(7):983–5.CrossRefGoogle Scholar
  27. 27.
    Stadlbauer V, Schaffellner S, Iberer F, et al. Occurrence of apoptosis during ischemia in porcine pancreas islet cells. Int J Artif Organs. 2003;26(3):205–10.PubMedGoogle Scholar
  28. 28.
    Baertschiger RM, Berney T, Morel P. Organ preservation in pancreas and islet transplantation. Curr Opin Organ Transplant. 2008;13(1):59–66.PubMedCrossRefGoogle Scholar
  29. 29.
    Nagata H, Matsumoto S, Okitsu T, et al. Procurement of the human pancreas for pancreatic islet transplantation from marginal cadaver donors. Transplantation. 2006;15;82(3):327–31.CrossRefGoogle Scholar
  30. 30.
    Kuroda Y, Kawamura T, Suzuki Y, et al. A new, simple method for cold storage of the pancreas using perfluorochemical. Transplantation. 1988;46(3):457.PubMedGoogle Scholar
  31. 31.
    Matsumoto S, Qualley SA, Goel S, et al. Effect of the two-layer (University of Wisconsin solution-perfluorochemical plus O2) method of pancreas preservation on human islet isolation, as assessed by the Edmonton isolation protocol. Transplantation. 2002;74(10):1414.PubMedCrossRefGoogle Scholar
  32. 32.
    Tsujimura T, Kuroda Y, Kin T, et al. Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method. Transplantation. 2002;74(12):1687.PubMedCrossRefGoogle Scholar
  33. 33.
    Ricordi C, Fraker C, Szust J, et al. Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation. 2003;75(9):1524.PubMedCrossRefGoogle Scholar
  34. 34.
    Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004;4(3):390.PubMedCrossRefGoogle Scholar
  35. 35.
    Jose Caballero-Corbalan, Torsten Eich, Torbjorn Lundgren, et al. No beneficial effect of two-layer storage compared with UW-storage on human islet isolation and transplantation. Transplantation. 2007;84(7):864–9.CrossRefGoogle Scholar
  36. 36.
    US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry, sterile drug products produced by aseptic processing—current good manufacturing practice September 2004.
  37. 37.
    US Department of Health and Human Services, Food and Drug Administration. The Code of Federal Regulations. Title 21: food and drugs, Parts 210 and 211.Google Scholar
  38. 38.
    US Department of Health and Human Services, Food and Drug Administration. The Code of Federal Regulations. Title 21: food and Drugs, Part 610.Google Scholar
  39. 39.
    US Department of Health and Human Services, Food and Drug Administration. The Code of Federal Regulations. Title 21: food and Drugs Parts 600 through 680.Google Scholar
  40. 40.
    Ricordi C. Human islet cell transplantation: new perspectives for an old challenge. Diabetes Rev. 1996;4:356–69.Google Scholar
  41. 41.
    Shapiro AM, Ricordi C. Unraveling the secrets of single donor. Success in islet transplantation. Am J Transplant. 2004;4(3):295–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Lakey JR, Burridge PW, Shapiro AM. Technical aspects of islet preparation and transplantation. Transpl Int. 2003;16(9):613–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Nakano M, Matsumoto I, Sawada T, et al. Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas. 2004;29(2):104–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Close NC, Hering BJ, Anand R, et al. (2003) Collaborative islet transplant registry (CITR). In: Cecka M, Terasaki P, editors. Clinical transplants, chapter 11. UCLA.Google Scholar
  45. 45.
    Hering BJ, Wijkstrom M, Eckman P. Islet transplantation: status, protocols and perspectives, Collaborative islet transplant registry (CITR). In: Gruessner RWG, Sutherland DER, editors. Transplantation of the pancreas, chapter 21. Berlin: Springer; 2004.Google Scholar
  46. 46.
    Okitsu T, Matsumoto S, Iwanaga Y, et al. Kyoto islet isolation method: the optimized one for non-heart-beating donors with highly efficient islet retrieval. Transplant Proc. 2005;37(8):3391–2.PubMedCrossRefGoogle Scholar
  47. 47.
    Yamamoto T, Ricordi C, Messinger S, et al. Deterioration and variability of highly purified collagenase blends used in clinical islet isolation. Transplantation. 2007;27;84(8):997–1002.CrossRefGoogle Scholar
  48. 48.
    Berney T, Molano RD, Cattan P, et al. Endotoxin-mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis. Transplantation. 2001;71:125–32.PubMedCrossRefGoogle Scholar
  49. 49.
    London NJ, Contractor H, Lake SP, et al. A microfluorometric viability assay for isolated human and rat islets of Langerhans. Diabetes Res. 1989;12(3):141.PubMedGoogle Scholar
  50. 50.
    Latif ZA, Noel J, Alejandro R. A simple method of staining fresh and cultured islets. Transplantation. 1988;45(4):827.PubMedCrossRefGoogle Scholar
  51. 51.
    Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat. 1990;27(3):185.PubMedCrossRefGoogle Scholar
  52. 52.
    Bank HL. Assessment of islet cell viability using fluorescent dyes. Diabetologia. 1987;30:812–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Bank HL. Rapid assessment of islet viability with acridine orange and propidium iodide. In Vitro Cell Dev Biol. 1988;24(4):266–73.PubMedCrossRefGoogle Scholar
  54. 54.
    Barnett MJ, McGhee-Wilson D, Shapiro AM, et al. Variation in human islet viability based on different membrane integrity stains. Cell Transplant. 2004;13:481–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Gerling IC, Kotb M, Fraga D, et al. No correlation between in vitro and in vivo function of human islets. Transplant Proc. 1998;30:587–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Eckhard M, Brandhorst D, Winter D, et al. The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. Transplant Proc. 2004;36:1528–31.PubMedCrossRefGoogle Scholar
  57. 57.
    McKay DB, Karow AM. Factors to consider in the assessment of viability of cryopreserved islets of Langerhans. Cryobiology. 1983;20:151–60.PubMedCrossRefGoogle Scholar
  58. 58.
    Lacy PE, Walker BS, Fink CJ. Perifusion of isolated rat islets in vitro: participation of the microtubular system in the biphasic release of insulin. Diabetes. 1972;21:987–8.PubMedGoogle Scholar
  59. 59.
    Socci C, Davalli AM, Vignali A, et al. Evidence of in vivo human islet graft function despite a weak response to in vitro perfusion. Transplant Proc. 1992;24:3056–7.PubMedGoogle Scholar
  60. 60.
    Ricordi C, Scharp DW, Lacy PE. Reversal of diabetes in nude mice after transplantation of fresh and 7-day-cultured (24°C) human pancreatic islets. Transplantation. 1988;45:994–6.PubMedGoogle Scholar
  61. 61.
    London NJ, Thirdborough SM, Swift SM, et al. The diabetic ‘‘human reconstituted’’ severe combined immunodeficient (SCID-hu) mouse: a model for isogeneic, allogeneic, and xenogeneic human islet transplantation. Transplant Proc. 1991;23:749.PubMedGoogle Scholar
  62. 62.
    Lake SP, Chamberlain J, Bassett PD, et al. Successful reversal of diabetes in nude rats by transplantation of isolated adult human islets of Langerhans. Diabetes. 1989;38:244–8.PubMedCrossRefGoogle Scholar
  63. 63.
    FDA Biological Response Modifier Advisory Committee Summary minutes meeting no. 36, 9–10 October 2003. Accessed 3 Dec 2008.
  64. 64.
    Ichii H, Inverardi L, Pileggi A, et al. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant. 2005;5(7):1635.PubMedCrossRefGoogle Scholar
  65. 65.
    Steinlechner-Maran R, Eberl T, Kunc M, et al. Respiratory defect as an early event in preservation-reoxygenation injury of endothelial cells. Transplantation. 1997;63:136–42.PubMedCrossRefGoogle Scholar
  66. 66.
    Yang H, Jia XM, Acker JP, et al. Routine assessment of viability in split-thickness skin. J Burn Care Rehabil. 2000;21:99–104.PubMedCrossRefGoogle Scholar
  67. 67.
    Zhang Y, Ohkohchi N, Oikawa K, et al. Assessment of viability of the liver graft in different cardiac arrest models. Transplant Proc. 2000;32:2345–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Steurer W, Stadlmann S, Roberts K, et al. Quality assessment of isolated pancreatic rat islets by high-resolution respirometry. Transplant Proc. 1999;31:650.PubMedCrossRefGoogle Scholar
  69. 69.
    Papas KK, Long RC Jr, Sambanis A, et al. Development of a bioartificial pancreas: I. long-term propagation and basal and induced secretion from entrapped betaTC3 cell cultures. Biotechnol Bioeng. 1999;66:219–30.PubMedCrossRefGoogle Scholar
  70. 70.
    Sweet IR, Khalil G, Wallen AR, et al. Continuous measurement of oxygen consumption by pancreatic islets. Diabetes Technol Ther. 2002;4:661–72.PubMedCrossRefGoogle Scholar
  71. 71.
    Papas KK, Wu H, Colton CK. Rapid islet quality assessment prior to transplantation. Cell Transplant. 2001;10:519.Google Scholar
  72. 72.
    Colton CK, Papas KK, Pisania A. Characterization of islet preparations. In: Halberstadt C, Emerich DF, et al. editors. Cell transplantation from laboratory to clinic. New York: Elsevier; 2006.Google Scholar
  73. 73.
    Fraker C, Timmins MR, Guarino RD, et al. The use of the BD oxygen biosensor system to assess isolated human islets of Langerhans: oxygen consumption as a potential measure of islet potency. Cell Transplant. 2006;15(8–9):745.PubMedCrossRefGoogle Scholar
  74. 74.
    Papas KK, Colton CK, Nelson RA, et al. Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice. Am J Transplant. 2007;7(3):707.PubMedCrossRefGoogle Scholar
  75. 75.
    Sweet IR, Gilbert M, Scott S, et al. Glucose-stimulated increment in oxygen consumption rate as a standardized test of human islet quality. Am J Transplant. 2008;8(1):183.PubMedGoogle Scholar
  76. 76.
    Takeuchi H, et al. Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem. 2005;280(11):10444–54.PubMedCrossRefGoogle Scholar
  77. 77.
    Ohshima S. Apoptosis and necrosis in senescent human fibroblasts. Ann N Y Acad Sci. 2006;1067:228–34.PubMedCrossRefGoogle Scholar
  78. 78.
    Burnett R, et al. DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA. TTC repeats in Friedreich’s ataxia. Proc Natl Acad Sci USA. 2006;103(31):11497–502.PubMedCrossRefGoogle Scholar
  79. 79.
    Varma H, et al. Inhibitors of metabolism rescue cell death in Huntington’s disease models. Proc Natl Acad Sci USA. 2007;104(36):14525–30.PubMedCrossRefGoogle Scholar
  80. 80.
    Bradbury DA, Simmons TD, Slater KJ, et al. Measurement of the ADP: ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis. J Immunol Methods. 2000;240:79–92.PubMedCrossRefGoogle Scholar
  81. 81.
    Goto M, Holgersson J, Kumagai-Braesch M, et al. The ADP/ATP ratio: a novel predictive assay for quality assessment of isolated pancreatic islets. Am J Transplant. 2006;6(10):2483–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Toshiyuki Yamamoto
    • 1
    • 2
  • Akihiko Horiguchi
    • 1
  • Masahiro Ito
    • 1
  • Hideo Nagata
    • 1
  • Hirohito Ichii
    • 2
  • Camillo Ricordi
    • 2
  • Shuichi Miyakawa
    • 1
  1. 1.Department of Surgery, School of MedicineFujita Health UniversityAichiJapan
  2. 2.Diabetes Research Institute, Miller School of MedicineUniversity of MiamiMiamiUSA

Personalised recommendations